18013 Background: Given the success of Stereotactic Body Radiotherapy (SBRT) for Non-
Small Cell Lung Carcinoma (NSCLC), early surrogates of local failure (LF) are necessary to …

Background We investigated the prognostic predictive value of the combination of
fluorodeoxyglucose (FDG)-and fluoromisonidazole (FMISO)-PET in patients with non-small …

Objective To examine disease control and survival after stereotactic body radiotherapy
(SBRT) for medically inoperable, early-stage non–small cell lung cancer (NSCLC) and …

PURPOSE: To investigate prognostic and risk factors for recurrence after stereotactic body
radiation therapy (SBRT) in patients with stage I non-small cell lung carcinoma (NSCLC) …

Aim To assess the utility of [18 F] FDG PET/CT quantitative parameters as prognostic factor
in patients diagnosed with localized and inoperable lung cancer treated by stereotactic body …

Purpose The use of stereotactic body radiation therapy (SBRT) has emerged as an effective
treatment modality for patients with early-stage non–small-cell lung cancer (NSCLC), with …

Background: Early identification of patients who fail to lung stereotactic body radiation
therapy (SBRT) is vital as they can benefit from salvage therapy. Main guidelines …

Background: The aim of our study was to evaluate the pattern of local failure after
Stereotactic Body Radiotherapy (SBRT) of Non Small Cell Lung Cancer (NSCLC) lesions …

Purpose Disease progression after definitive stereotactic body radiation therapy (SBRT) for
early-stage non-small cell lung cancer (NSCLC) occurs in 20–40% of patients. Here, we …

Background/Aim: Radiological evaluation after stereotactic-body-radiotherapy (SBRT) for
non-small-cell lung carcinoma (NSCLC) is often difficult due to lung radiation-induced image …